Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study
Arthritis Care & Research · 15.03.2009 · 61 (3) · 344-352
DOI: 10.1002/art.24096 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis Care & Research, online erschienen am 26.02.2009. Verfasst von X Chevalier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Henri Mondor, University Paris XII, Créteil, France. xavier.chevalier@hmn.ap-hop-paris.fr. Die Arbeit wurde bisher 499-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
To evaluate the clinical response, safety, and tolerability of a single intraarticular injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee.
Methods
Patients with OA of the knee were enrolled in a multicenter, double‐blind, placebo‐controlled study and randomized 2:1:2 to receive a single intraarticular injection of placebo, anakinra 50 mg, or anakinra 150 mg in their symptomatic knee. Patients were evaluated for 12 weeks postinjection. The primary end point was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline to week 4. Safety assessments included the evaluation of adverse events (AEs), laboratory tests, and vital signs. Pharmacokinetic parameters were assessed in a subset of patients.
Results
Of 170 patients who enrolled, 160 (94%) completed the study. The mean improvements from baseline to week 4 in the WOMAC score were not statistically different between the placebo group and the patients who received 50 mg of anakinra ( P = 0.67) or 150 mg of anakinra ( P = 0.77). Anakinra was well tolerated. No withdrawals due to AEs or serious AEs, and no serious infections or deaths were reported. No clinically significant trends were noted in laboratory values or vital signs. Pharmacokinetic parameters demonstrated that the mean terminal half‐life of anakinra in serum after intraarticular injection was ∼4 hours.
Conclusion
Anakinra was well tolerated as a single 50‐mg or 150‐mg intraarticular injection in patients with OA of the knee. However, anakinra was not associated with improvements in OA symptoms compared with placebo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Hospital Henri Mondor, University Paris XII, Créteil, France. xavier.chevalier@hmn.ap-hop-paris.fr
Zitieren
APA
Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., Loeuille, D., Kivitz, A. J., Silver, D., & Appleton, B. E. (2009). Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis Care & Research, 61(3), 344-352. https://doi.org/10.1002/art.24096
Vancouver
Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis Care & Research. 2009;61(3):344-352. doi:10.1002/art.24096
BibTeX
@article{Chevalier2009,
author = {Chevalier, X and Goupille, P and Beaulieu, A D and Burch, F X and Bensen, W G and Conrozier, T and Loeuille, D and Kivitz, A J and Silver, D and Appleton, B E},
title = {Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study},
journal = {Arthritis Care & Research},
year = {2009},
volume = {61},
number = {3},
pages = {344--352},
doi = {10.1002/art.24096}
}
EUVIMED